Dissecting the Pattern of Nodal Spread in Post-neoadjuvant Pancreatoduodenectomy

Sponsor
Universita di Verona (Other)
Overall Status
Recruiting
CT.gov ID
NCT06135649
Collaborator
(none)
850
1
143
5.9

Study Details

Study Description

Brief Summary

There has been long-standing debate about nodal dissection in pancreatoduodenectomy (PD) for pancreatic ductal adenocarcinoma (PDAC), with most studies examining the value of nodal yields, number of metastatic nodes and spatial location of metastases being conducted in the upfront surgery setting. With increasing use of a chemotherapy-first approach even in early stage PDAC, the validity of nodal parameters in post-treatment PD has been brought into question due to therapy-induced lymph node (LN) shrinkage. However, the available information is based on retrospective data or administrative registries, which only considered the number of examined and metastatic nodes, without detailed information regarding the dissection protocol and the influence of nodal metastases location. Back in 2013, corresponding to the standard lymphadenectomy definition release by the International Study Group of Pancreatic Surgery (ISGPS) and the diffusion of multi-agent chemotherapy regimens, an institutional, station-based nodal dissection protocol was established for post-neoadjuvant PD. The aim was to investigate whether the pattern of metastatic spread within the nodal basin is a superior quality metric for prognosis relative to the count-based classification system.

Condition or Disease Intervention/Treatment Phase
  • Procedure: Systematic lymphadenectomy

Study Design

Study Type:
Observational [Patient Registry]
Anticipated Enrollment :
850 participants
Observational Model:
Cohort
Time Perspective:
Prospective
Official Title:
A Prospective Lymphadenectomy Protocol to Investigate the Pattern of Nodal Spread and Its Association With Oncologic Outcomes in Post-neoadjuvant Pancreatoduodenectomy
Actual Study Start Date :
Jan 1, 2013
Actual Primary Completion Date :
Dec 1, 2019
Anticipated Study Completion Date :
Dec 1, 2024

Outcome Measures

Primary Outcome Measures

  1. Metastatic involvement of second nodal echelon [3 years]

    Rate of metastases to nodes outside the main resection specimen (stations 6,8,12)

Secondary Outcome Measures

  1. Metastatic involvement of single nodal stations [8 years]

    Rate of metastases in each station included in the lymphadenectomy protocol

  2. Overall survival [3 years]

    Overall survival from pancreatectomy stratified by nodal echelon

  3. Recurrence-free survival [3 years]

    Recurrence-free survival from pancreatectomy stratified by nodal echelon

  4. Overall survival [8 years]

    Overall survival from pancreatectomy stratified by nodal stations

  5. Recurrence-free survival [8 years]

    Recurrence-free survival from pancreatectomy stratified by nodal stations

Eligibility Criteria

Criteria

Ages Eligible for Study:
N/A and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Post-neoadjuvant pancreatoduodenectomy for localized pancreatic ductal adenocarcinoma.
Exclusion Criteria:
  • Oligometastatic disease

  • Upfront pancreatectomy

  • Incomplete lymphadenectomy

  • Macroscopically incomplete resections

  • Rare variants of pancreatic cancer

Contacts and Locations

Locations

Site City State Country Postal Code
1 Unit of Pancreatic Surgery - G.B. Rossi Hospital, University of Verona Hospital Trust Verona VR Italy 37134

Sponsors and Collaborators

  • Universita di Verona

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
Giuseppe Malleo, Associate Professor of Surgery, Universita di Verona
ClinicalTrials.gov Identifier:
NCT06135649
Other Study ID Numbers:
  • LN_NAT
First Posted:
Nov 18, 2023
Last Update Posted:
Nov 18, 2023
Last Verified:
Nov 1, 2023
Individual Participant Data (IPD) Sharing Statement:
Undecided
Plan to Share IPD:
Undecided
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Giuseppe Malleo, Associate Professor of Surgery, Universita di Verona
Additional relevant MeSH terms:

Study Results

No Results Posted as of Nov 18, 2023